Want to see IN:KILITCH full AI Analyst Report?
Top Page
Kilitch Drugs (India) Limited
(KILITCH)
Select Model
Select Model
Rating:63Neutral
Price Target:
₹227.00
▲(15.85% Upside)
Action:Reiterated
Date:09/23/26
The score is most constrained by weak cash generation (persistently negative and worsening free cash flow alongside rising debt) despite solid revenue growth and decent profitability. Technicals are supportive due to a strong uptrend, but overbought momentum signals temper that benefit. Valuation appears moderate (P/E ~23.9) without dividend support.
Positive Factors
Strong revenue growth
The substantial increase in revenue over several years indicates meaningful business expansion and continued demand for the company’s pharmaceutical formulations. Maintaining growth at scale can strengthen market reach, support operating investment, and provide a durable base for future earnings.
Negative Factors
Persistently negative free cash flow
Persistent negative free cash flow means reported growth and earnings are not translating into available cash for reinvestment, debt reduction, or shareholder returns. The sharp deterioration in 2026 increases the risk that expansion will require continued external funding if the pattern persists.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong revenue growth
The substantial increase in revenue over several years indicates meaningful business expansion and continued demand for the company’s pharmaceutical formulations. Maintaining growth at scale can strengthen market reach, support operating investment, and provide a durable base for future earnings.
Read all positive factors
Kilitch Drugs (India) Limited (KILITCH) vs. iShares MSCI India ETF (INDA)
Market Cap
₹7.71B
Dividend Yield0.4%
Average Volume (3M)4.85K
Price to Earnings (P/E)24.2
Beta (1Y)0.91
Revenue Growth14.04%
EPS Growth2.57%
CountryIN
Employees236
SectorGeneral
Sector StrengthN/A
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)8.82
Shares Outstanding34,961,563
10 Day Avg. Volume8,844
30 Day Avg. Volume4,852
Financial Highlights & Ratios
PEG Ratio1.44
Price to Book (P/B)1.51
Price to Sales (P/S)1.79
P/FCF Ratio-5.23
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)7.5
Revenue Forecast (FY)₹2.64B
Kilitch Drugs (India) Limited Business Overview & Revenue Model
Company Description
Kilitch Drugs (India) Limited, established in 1978 and based in Mumbai, operates a comprehensive pharmaceutical enterprise involved in the development and distribution of a wide array of medicinal and related products, both within India and for ex...
How the Company Makes Money
Kilitch Drugs (India) Limited primarily makes money by selling pharmaceutical finished dosage formulations (i.e., manufactured drug products) to customers in India and in international markets. Its revenue model is centered on: (1) Branded and/or ...
Kilitch Drugs (India) Limited Financial Statement Overview
Summary
Income Statement
74
Positive
Balance Sheet
71
Positive
Cash Flow
38
Negative
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.37B | 2.35B | 1.98B | 1.54B | 1.40B | 1.14B |
| Gross Profit | 925.29M | 914.13M | 937.39M | 731.38M | 624.64M | 337.44M |
| EBITDA | 434.24M | 478.38M | 426.26M | 287.43M | 206.50M | 134.13M |
| Net Income | 300.53M | 301.66M | 267.01M | 146.01M | 104.48M | 73.67M |
Balance Sheet | ||||||
| Total Assets | 0.00 | 4.58B | 3.13B | 2.40B | 2.20B | 2.10B |
| Cash, Cash Equivalents and Short-Term Investments | 687.39M | 687.39M | 593.98M | 690.19M | 591.77M | 572.43M |
| Total Debt | 0.00 | 887.09M | 494.24M | 316.46M | 221.94M | 204.32M |
| Total Liabilities | -2.77B | 1.81B | 1.12B | 643.88M | 689.41M | 695.55M |
| Stockholders Equity | 2.77B | 2.80B | 2.02B | 1.76B | 1.52B | 1.39B |
Cash Flow | ||||||
| Free Cash Flow | -581.23M | -805.64M | -293.31M | -65.97M | -12.26M | -24.19M |
| Operating Cash Flow | -66.20M | 189.43M | 175.42M | -1.46M | 25.86M | 57.83M |
| Investing Cash Flow | -514.49M | -1.01B | -399.47M | -95.45M | 79.15M | -152.50M |
| Financing Cash Flow | 813.60M | 880.13M | 132.43M | 88.07M | -7.16M | 70.28M |
Kilitch Drugs (India) Limited Technical Analysis
Positive
195.95
Price Trends
185.98
Positive
183.09
Positive
171.44
Positive
Market Momentum
11.36
Negative
70.54
Negative
75.82
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:KILITCH, the sentiment is Positive. The current price of 195.95 is above the 20-day moving average (MA) of 195.23, above the 50-day MA of 185.98, and above the 200-day MA of 171.44, indicating a bullish trend. The MACD of 11.36 indicates Negative momentum. The RSI at 70.54 is Negative, neither overbought nor oversold. The STOCH value of 75.82 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:KILITCH.
Kilitch Drugs (India) Limited Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
63 Neutral | ₹7.71B | 24.17 | ― | 0.40% | 14.04% | 2.57% | |
60 Neutral | ₹4.39B | 40.17 | ― | 0.31% | 24.66% | 10.89% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
55 Neutral | ₹5.01B | 22.06 | ― | 0.57% | 11.43% | 258.53% | |
50 Neutral | ₹6.62B | 42.79 | ― | ― | 89.64% | 10627.64% | |
50 Neutral | ₹7.17B | 168.26 | ― | 0.15% | 7.55% | -57.19% | |
48 Neutral | ₹2.08B | -0.92 | ― | 20.72% | -99.53% | -41.93% |
* General Sector Average
IN:KILITCH
Kilitch Drugs (India) Limited
214.55
41.73
24.14%
IN:ALBERTDAVD
Albert David Ltd
871.80
99.46
12.88%
IN:MEDICAMEQ
Medicamen Biotech Limited
326.75
26.32
8.76%
IN:NECLIFE
Nectar Lifesciences Ltd.
10.35
-3.86
-27.16%
IN:VALIANTLAB
Valiant Laboratories Ltd.
126.55
42.92
51.32%
IN:ZIMLAB
Zim Laboratories Ltd.
137.95
65.95
91.60%
Kilitch Drugs (India) Limited Corporate Events
Kilitch Drugs conducts fully virtual 34th AGM, highlights performance and governance
Aug 27, 2026
Kilitch Drugs (India) Limited held its 34th Annual General Meeting on August 27, 2026, conducted entirely via video conferencing in line with Companies Act and regulatory guidelines. The virtual AGM, attended by the full board, key management, sta...
Kilitch Drugs Files SEBI-Compliant Monitoring Report for June Quarter
Aug 18, 2026
Kilitch Drugs (India) Limited has submitted a monitoring agency report for the quarter ended June 30, 2026 to BSE and NSE, in line with disclosure requirements under SEBI’s listing and capital issue regulations. The report, prepared by Infom...
Kilitch Drugs Publishes Quarterly Results in Marathi and English Dailies
Aug 18, 2026
Kilitch Drugs (India) Limited has reported that extracts of its financial results for the quarter ended 30 June 2026 have been published in both Marathi and English newspapers. The publication, dated 15 August 2026, fulfills the company’s re...
Kilitch Drugs Announces Trading Window Closure Ahead of Q1 FY27 Results
Jun 26, 2026
Kilitch Drugs (India) Limited has announced the closure of its trading window for designated persons and their immediate relatives from 1 July 2026, in line with SEBI’s Prohibition of Insider Trading Regulations and the company’s own c...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.